233 related articles for article (PubMed ID: 23319287)
1. In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.
Goutelle S; Bourguignon L; Bleyzac N; Berry J; Clavel-Grabit F; Tod M
AAPS J; 2013 Apr; 15(2):415-26. PubMed ID: 23319287
[TBL] [Abstract][Full Text] [Related]
2. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.
Castellan AC; Tod M; Gueyffier F; Audars M; Cambriels F; Kassaï B; Nony P;
Clin Pharmacokinet; 2013 Mar; 52(3):199-209. PubMed ID: 23344982
[TBL] [Abstract][Full Text] [Related]
3. Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model.
Fermier N; Bourguignon L; Goutelle S; Bleyzac N; Tod M
Clin Pharmacokinet; 2018 Dec; 57(12):1581-1591. PubMed ID: 29572664
[TBL] [Abstract][Full Text] [Related]
4. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.
Gong J; Iacono L; Iyer RA; Humphreys WG; Zheng M
Br J Clin Pharmacol; 2018 Jun; 84(6):1335-1345. PubMed ID: 29469197
[TBL] [Abstract][Full Text] [Related]
6. How precise is quantitative prediction of pharmacokinetic effects due to drug-drug interactions and genotype from in vitro data? A comprehensive analysis on the example CYP2D6 and CYP2C19 substrates.
Dücker C; Brockmöller J
Pharmacol Ther; 2021 Jan; 217():107629. PubMed ID: 32682785
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
[TBL] [Abstract][Full Text] [Related]
8. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
Desta Z; Zhao X; Shin JG; Flockhart DA
Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of clopidogrel: evidence and perspectives.
Yin T; Miyata T
Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545
[TBL] [Abstract][Full Text] [Related]
11. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance.
Rosemary J; Adithan C
Curr Clin Pharmacol; 2007 Jan; 2(1):93-109. PubMed ID: 18690857
[TBL] [Abstract][Full Text] [Related]
12. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
13. Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics.
Choi CI; Bae JW; Lee YJ; Lee HI; Jang CG; Lee SY
J Clin Psychopharmacol; 2014 Feb; 34(1):139-42. PubMed ID: 24346747
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.
Kobayashi K; Morita J; Chiba K; Wanibuchi A; Kimura M; Irie S; Urae A; Ishizaki T
Pharmacogenetics; 2004 Aug; 14(8):549-56. PubMed ID: 15284537
[TBL] [Abstract][Full Text] [Related]
15. Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure.
Yeo KR; Kenny JR; Rostami-Hodjegan A
Eur J Clin Pharmacol; 2013 Jun; 69(6):1311-20. PubMed ID: 23307233
[TBL] [Abstract][Full Text] [Related]
16. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.
Li-Wan-Po A; Girard T; Farndon P; Cooley C; Lithgow J
Br J Clin Pharmacol; 2010 Mar; 69(3):222-30. PubMed ID: 20233192
[TBL] [Abstract][Full Text] [Related]
18. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
Price MJ; Tantry US; Gurbel PA
Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
[TBL] [Abstract][Full Text] [Related]
19. Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.
Grün B; Merkel U; Riedel KD; Weiss J; Mikus G
Br J Clin Pharmacol; 2012 Nov; 74(5):854-63. PubMed ID: 22381043
[TBL] [Abstract][Full Text] [Related]
20. How Informative Are Drug-Drug Interactions of Gene-Drug Interactions?
Lagishetty CV; Deng J; Lesko LJ; Rogers H; Pacanowski M; Schmidt S
J Clin Pharmacol; 2016 Oct; 56(10):1221-31. PubMed ID: 27040602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
